Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vector-based therapies can effectively correct some disease pathology in murine models with mucopolysaccharidoses. However, immunogenicity can limit therapeutic effect as immune responses target capsid proteins, transduced cells, and gene therapy products, ultimately resulting in loss of enzyme activity. Inherent differences in male versus female immune response can significantly impact AAV gene transfer. We aim to investigate sex differences in the immune response to AAV gene therapies in mice with mucopolysaccharidosis IVA (MPS IVA). MPS IVA mice, treated with different AAV vectors expressing human N-acetylgalactosamine 6-sulfate sulfatase (GALNS), demonstrated a more robust antibody response in female mice resulting in subsequent decreased GALNS enzyme activity and less therapeutic efficacy in tissue pathology relative to male mice. Under thyroxine-binding globulin promoter, neutralizing antibody titers in female mice were approximately 4.6-fold higher than in male mice, with GALNS enzyme activity levels approximately 6.8-fold lower. Overall, male mice treated with AAV-based gene therapy showed pathological improvement in the femur and tibial growth plates, ligaments, and articular cartilage as determined by contrasting differences in pathology scores compared to females. Cardiac histology revealed a failure to normalize vacuolation in females, in contrast, to complete correction in male mice. These findings promote the need for further determination of sex-based differences in response to AAV-mediated gene therapy related to developing treatments for MPS IVA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Cassette and study design. The experimental scheme of the first study was described by Sawamoto et al. [23]. AAV8: adeno-associated virus 8, ITR: inverted terminal repeat, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, D8: aspartic acid octapeptide, hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, RBG pA: rabbit β globin poly-A tail.](https://figures.cochat.ai/paper-figures/906c9366651941619f6f6339dcc55566/sex-difference-leads-to-differential-gene-expression-patterns-and-therapeutic-figure-1.jpg)








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may lead to a stronger adaptive response in AAV gene therapy in females with greater cell and antibody-mediated immunity directed against the transgene product resulting in poorer treatment durability (Piechnik et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Piechnik et al., 2022
Experimental — accuracy not yet measuredIn the citing paper
“Sex differences in transgene expression have been observed in pre-clinical studies with AAV delivery to liver or systemically,59,60 with females showing lower levels of transgene expression, linked to both sex hormones59 and a more robust humoral immune response in females.60”
From Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age (2025) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370 · cited 3×
“In mammals, females have been shown to mount more robust immune responses, innate and adaptive, compared to males [26].”
BackgroundInfluentialAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“Several strategies have been employed to overcome the immune response, including liver targeting to induce immune tolerance [17,18] and the use of steroids to inhibit T cell responses against the capsid to provide durable transgene expression [18,19] being the most well-known methods in clinical and preclinical models…”
MethodAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“AAV has been shown to efficiently transduce target cells, induce high enzyme activity levels in target tissues, and achieve sustainable long-term enzyme expression [12,13].”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
Grieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Rettew, J. A., Huet-Hudson, Y. M., & Marriott, I. (2008) · Biology of Reproduction · doi:10.1095/biolreprod.107.063545 · Cited by 376
Sugimoto, C. R., Ahn, Y.-Y., Smith, E., Macaluso, B., & Larivière, V. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32995-7 · Cited by 305
Klein, S. L. (2012) · BioEssays · doi:10.1002/bies.201200099 · Cited by 284 · cited 1×
“Likely, the differences observed between males and females link back to the interactions between sex-specific hormones and their propensity for immune-modulatory receptors such as the NF-κB, cJun, and interferon regulatory factor 1 pathways [42,43].”
BackgroundMcIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278 · cited 1×
“Several strategies have been employed to overcome the immune response, including liver targeting to induce immune tolerance [17,18] and the use of steroids to inhibit T cell responses against the capsid to provide durable transgene expression [18,19] being the most well-known methods in clinical and preclinical models…”
MethodSex-associated differences in the regulation of immune responses controlled by the MHC of the mouse.
Weinstein, Y., Ran, S., & Segal, S. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.2.656 · Cited by 260
Davidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244 · cited 3×
“The immune response disparity between male and female mice in this study was similar to the pattern of immunogenic sex differences previously demonstrated [24,25].”
BackgroundResultUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
A splice variant of human Bmal1 acts as a negative regulator of the molecular circadian clock
Lee, J., Park, E., Kim, G. H., Kwon, I., & Kim, K. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0187-x · Cited by 200
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178 · cited 2×
“Regarding viral response, both female rats and women elicit a more robust innate response by demonstrating more significant cytokine upregulation induced by TLR-MyD88 pathway activation as a primary response to AAV vectors and the production of antibodies in response to viral challenges [35].”
BackgroundZuk, M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000267 · Cited by 168 · cited 1×
“Male mice utilize more resources for sexual fitness, and female mice dedicate more resources to survival [34].”
BackgroundSex Hormones and Immunity to Infection
(2010) · Springer eBooks · doi:10.1007/978-3-642-02155-8 · Cited by 162
Kurtz, J., Wiesner, A., Götz, P., & Sauer, K. P. (2000) · Developmental & Comparative Immunology · doi:10.1016/s0145-305x(99)00057-9 · Cited by 160
Torcia, M. G., Nencioni, L., Clemente, A. M., Civitelli, L., Celestino, I., Limongi, D., Fadigati, G., Perissi, E., Cozzolino, F., Garaci, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039853 · Cited by 151 · cited 1×
“reported that stimulation of TLR9 induced higher production of the immunosuppressive cytokine IL10 in males, which reduced the overall strength of the male innate immune response [41].”
BackgroundAAV-Mediated Liver-Directed Gene Therapy
Sands, M. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_6 · Cited by 132 · cited 2×
“Additionally, incorporating liver-specific promoters can increase hepatocyte specificity and reduce off-target transgene production [22].”
BackgroundOguma, T., Tomatsu, S., Montaño, A. M., & Okazaki, O. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.05.016 · Cited by 131
Self-citationMucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
Sawamoto, K., Álvarez González, J., Piechnik, M., Otero, F., Couce, M., Suzuki, Y., & Tomatsu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041517 · Cited by 129 · cited 2×
“Even though HSCT shows some impact on the improvement of bone and cartilage pathology, the approach is associated with other limitations such as the risk of graft versus host disease (GVHD), challenges in donor matching, graft rejection, and the need for well-trained staff and suitably equipped clinical facility for s…”
BackgroundMethodSelf-citationMortality in Patients with Morquio Syndrome A
Lavery, C., & Hendriksz, C. J. (2014) · JIMD Reports · doi:10.1007/8904_2014_298 · Cited by 117 · cited 1×
“The mean age of death in MPS IVA patients is in the third decade, with respiratory failure causing two-thirds of patient deaths [4].”
BackgroundMucopolysaccharidosis IVA and glycosaminoglycans
Khan, S. A., Alméciga-Díaz, C. J., Sawamoto, K., Mackenzie, W. G., Theroux, M. C., Pizarro, C., Mason, R. W., Orii, T., & Tomatsu, S. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.007 · Cited by 115 · cited 1×
“Mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome, is an autosomal recessive metabolic lysosomal disorder caused by a deficiency of the lysosomal N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme, which leads to the accumulation of keratan sulfate (KS) and chondroitin-6-sulfate (C6S), mainly in bone an…”
BackgroundSelf-citationFARGALLO, J. A., MARTÍNEZ‐PADILLA, J., TOLEDANO‐DÍAZ, A., SANTIAGO‐MORENO, J., & DÁVILA, J. A. (2007) · Journal of Animal Ecology · doi:10.1111/j.1365-2656.2006.01193.x · Cited by 113
Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
Mackus, W. J. M., Frakking, F. N. J., Grummels, A., Gamadia, L. E., de Bree, G. J., Hamann, D., van Lier, R. A. W., & van Oers, M. H. J. (2003) · Blood · doi:10.1182/blood-2003-01-0182 · Cited by 102
Tomatsu, S., Orii, K. O., Vogler, C., Nakayama, J., Levy, B., Grubb, J. H., Gutierrez, M. A., Shim, S., Yamaguchi, S., Nishioka, T., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg366 · Cited by 99 · cited 1×
“As previously described, the MPS IVA knock-out mouse (MKC; Galns-/-) was developed via targeted disruption of exon 2 of GALNS [23,50].”
BackgroundSelf-citationHematopoietic stem cell transplantation for Morquio A syndrome
Yabe, H., Tanaka, A., Chinen, Y., Kato, S., Sawamoto, K., Yasuda, E., Shintaku, H., Suzuki, Y., Orii, T., & Tomatsu, S. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.09.011 · Cited by 92
Self-citationEnhancement of Drug Delivery: Enzyme-replacement Therapy for Murine Morquio A Syndrome
Tomatsu, S., Montaño, A. M., Dũng, V. C., Ohashi, A., Oikawa, H., Oguma, T., Orii, T., Barrera, L. A., & Sly, W. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.32 · Cited by 89 · cited 1×
“Assessment of reduction of storage materials were described previously [60,61].”
BackgroundSelf-citationWang, J., Luan, Z., Jiang, H., Fang, J., Qin, M., Lee, V., & Chen, J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.015 · Cited by 86
Balance of the Sexes: Addressing Sex Differences in Preclinical Research.
Zakiniaeiz, Y., Cosgrove, K., Potenza, M. N., & Mazure, C. M. (2016) · PubMed Central · Cited by 83
Mondal, S., & Rai, U. (1999) · General and Comparative Endocrinology · doi:10.1006/gcen.1999.7370 · Cited by 81
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81 · cited 1×
“Several strategies have been employed to overcome the immune response, including liver targeting to induce immune tolerance [17,18] and the use of steroids to inhibit T cell responses against the capsid to provide durable transgene expression [18,19] being the most well-known methods in clinical and preclinical models…”
MethodEnhancing transduction of the liver by adeno-associated viral vectors
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., & Davidoff, A. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.137 · Cited by 77
Sex Steroid Receptors in Immune Cells
Kovats, S., Carreras, E., & Agrawal, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-02155-8_3 · Cited by 76 · cited 1×
“Likely, the differences observed between males and females link back to the interactions between sex-specific hormones and their propensity for immune-modulatory receptors such as the NF-κB, cJun, and interferon regulatory factor 1 pathways [42,43].”
BackgroundTomatsu, S., Sawamoto, K., Shimada, T., Bober, M. B., Kubaski, F., Yasuda, E., Mason, R. W., Khan, S. A., Alméciga-Díaz, C. J., Barrera, L. A., et al. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1086640 · Cited by 70 · cited 2×
“Current treatment for MPS IVA includes enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), both of which have a limited impact on the characteristic skeletal dysplasia [5,6].”
MethodSelf-citationKubaski, F., Mason, R. W., Nakatomi, A., Shintaku, H., Xie, L., van Vlies, N., Church, H. J., Giugliani, R., Kobayashi, H., Yamaguchi, S., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9981-6 · Cited by 69
Self-citationMorquio A syndrome: diagnosis and current and future therapies.
Tomatsu, S., Yasuda, E., Patel, P., Ruhnke, K., Shimada, T., Mackenzie, W. G., Mason, R. W., Thacker, M. M., Theroux, M. C., Montaño, A. M., et al. (2014) · PubMed · Cited by 65
Self-citationTetrasulfated Disaccharide Unit in Heparan Sulfate
Mochizuki, H., Yoshida, K., Shibata, Y., & Kimata, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801586200 · Cited by 65
Oguma, T., Tomatsu, S., & Okazaki, O. (2007) · Biomedical Chromatography · doi:10.1002/bmc.760 · Cited by 64
Self-citationTomatsu, S., Gutierrez, M. A., Nishioka, T., Yamada, M., Yamada, M., Tosaka, Y., Grubb, J. H., Montaño, A. M., Vieira, M. B., Trandafirescu, G. G., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi364 · Cited by 64
Self-citationChinen, Y., Higa, T., Tomatsu, S., Suzuki, Y., Orii, T., & Hyakuna, N. (2014) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2013.11.002 · Cited by 63
Self-citationEffect of enzyme replacement therapy on the growth of patients with Morquio A
Doherty, C., Stapleton, M., Piechnik, M., Mason, R. W., Mackenzie, W. G., Yamaguchi, S., Kobayashi, H., Suzuki, Y., & Tomatsu, S. (2019) · Journal of Human Genetics · doi:10.1038/s10038-019-0604-6 · Cited by 60 · cited 1×
“ERT, approved for clinical use for MPS IVA by the Food and Drug Administration in 2014, requires weekly infusions at a high cost [6], demonstrates a short half-life [7], and has not shown a significant impact in correcting growth and skeletal pathology [8].”
MethodSelf-citationGender differences in the immune system activities of sea urchin Paracentrotus lividus
Arizza, V., Vazzana, M., Schillaci, D., Russo, D., Giaramita, F. T., & Parrinello, N. (2012) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.11.021 · Cited by 58
Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB
Shimada, T., Tomatsu, S., Mason, R. W., Yasuda, E., Mackenzie, W. G., Hossain, J., Shibata, Y., Montaño, A. M., Kubaski, F., Giugliani, R., et al. (2014) · JIMD Reports · doi:10.1007/8904_2014_330 · Cited by 58
Self-citationGene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
Fraldi, A., Serafini, M., Sorrentino, N. C., Gentner, B., Aiuti, A., & Bernardo, M. E. (2018) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-018-0565-y · Cited by 57 · cited 1×
“AAV has been shown to efficiently transduce target cells, induce high enzyme activity levels in target tissues, and achieve sustainable long-term enzyme expression [12,13].”
BackgroundChondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII
Shimada, T., Tomatsu, S., Yasuda, E., Mason, R. W., Mackenzie, W. G., Shibata, Y., Kubaski, F., Giugliani, R., Yamaguchi, S., Suzuki, Y., et al. (2014) · JIMD Reports · doi:10.1007/8904_2014_311 · Cited by 49
Self-citationMouse Gender Influences Brain Transduction by Intravascularly Administered AAV9
Maguire, C. A., Crommentuijn, M. H., Mu, D., Hudry, E., Serrano-Pozo, A., Hyman, B. T., & Tannous, B. A. (2013) · Molecular Therapy · doi:10.1038/mt.2013.95 · Cited by 47 · cited 2×
“The immune response disparity between male and female mice in this study was similar to the pattern of immunogenic sex differences previously demonstrated [24,25].”
BackgroundResultX-Linked Variation in Immune Response in Drosophila melanogaster
Hill‐Burns, E. M., & Clark, A. G. (2009) · Genetics · doi:10.1534/genetics.108.093971 · Cited by 42
Tomatsu, S., Montaño, A. M., Oikawa, H., Dũng, V. C., Hashimoto, A., Oguma, T., Gutiérrez, M. L., Takahashi, T., Shimada, T., Orii, T., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.05.013 · Cited by 42 · cited 1×
“Assessment of reduction of storage materials were described previously [60,61].”
BackgroundSelf-citationQi, Y., Musson, D. G., Schweighardt, B., Tompkins, T., Jesaitis, L. A., Shaywitz, A. J., Yang, K., & O’neill, C. A. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0173-y · Cited by 39 · cited 1×
“ERT, approved for clinical use for MPS IVA by the Food and Drug Administration in 2014, requires weekly infusions at a high cost [6], demonstrates a short half-life [7], and has not shown a significant impact in correcting growth and skeletal pathology [8].”
MethodSawamoto, K., Karumuthil‐Melethil, S., Khan, S. A., Stapleton, M., Bruder, J. T., Danos, O., & Tomatsu, S. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.015 · Cited by 38 · cited 9×
“We demonstrated partial efficacy in improving skeletal and cardiovascular pathology [23].”
BackgroundMethodResultInfluentialSelf-citationToietta, G., Severini, G. M., Traversari, C., Tomatsu, S., Sukegawa, K., Fukuda, S., Kondo, N., Tortora, P., & Bordignon, C. (2001) · Human Gene Therapy · doi:10.1089/104303401753204571 · Cited by 36 · cited 1×
“The previously described protocols [51] determined activity levels of GALNS.”
Self-citationActivity of daily living for Morquio A syndrome
Yasuda, E., Suzuki, Y., Shimada, T., Sawamoto, K., Mackenzie, W. G., Theroux, M. C., Pizarro, C., Xie, L., Miller, F., Rahman, T., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.04.005 · Cited by 35
Self-citationMuenzer, J., Prada, C. E., Burton, B. K., Lau, H., Ficicioglu, C. H., Foo, C. W. P., Vaidya, S. A., Whitley, C. B., & Harmatz, P. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.12.263 · Cited by 27
Tomatsu, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg119 · Cited by 23
Self-citationIt is time to integrate sex as a variable in preclinical and clinical studies
Lee, H., Pak, Y. K., Yeo, E., Kim, Y. S., Paik, H. Y., & Lee, S. K. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0122-1 · Cited by 20
Evading the AAV Immune Response in Mucopolysaccharidoses
Piechnik, M., Sawamoto, K., Ohnishi, H., Kawamoto, N., Ago, Y., & Tomatsu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103433 · Cited by 12 · cited 1×
“Several strategies have been employed to overcome the immune response, including liver targeting to induce immune tolerance [17,18] and the use of steroids to inhibit T cell responses against the capsid to provide durable transgene expression [18,19] being the most well-known methods in clinical and preclinical models…”
MethodSelf-citation(2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.037 · Cited by 8 · cited 1×
“Their findings suggest a negative correlation between circulating female hormone levels and enzyme activity [40].”
BackgroundChondroitin 6-sulfate as a novel biomarker for mucopolysaccharidosis IVA and VII
Kubaski, F., Shimada, T., Tomatsu, S., Yasuda, E., Mason, R. W., Mackenzie, W. G. S., Shibata, Y., Giugliani, R., Yamaguchi, S., Suzuki, Y., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.12.141 · Cited by 1
Self-citation
Cited by
A comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“This may lead to a stronger adaptive response in AAV gene therapy in females with greater cell and antibody-mediated immunity directed against the transgene product resulting in poorer treatment durability (Piechnik et al., 2022).”
Giles, A. R., Lock, M. W., Chen, S., Turner, K. B., Wesolowski, G. A., Prongay, A., Petkov, B., Olagbegi, K., Yan, H., & Wilson, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.116 · Cited by 23
“19 Considering the established nature of this phenomenon in the literature, further pursuit of sex-based differences was deemed unnecessary.”
Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age
Clare, A. J., Langer, P. M., Ward, A., Chan, Y. K., Dick, A. D., & Copland, D. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.028 · Cited by 19
Metadata
- Authors
- Piechnik, M., Amendum, P. C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., Álvarez, V., Pachon, A. M. H., Danos, O., Bruder, J. T., Karumuthil-Melethil, S., & Tomatsu, S.
- Affiliations
- Alfred I. duPont Hospital for Children (US)
- Philadelphia College of Osteopathic Medicine (US)
- Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE 19803, USA
- Regenxbio (United States) (US)
- REGENXBIO Inc., Rockville, MD 20850, USA
- Corresponding author
- Tomatsu, Shunji
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-21
- Volume
- 23
- Issue
- 20
- Pages
- 12693
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9604118
- OpenAlex
- W4307263165
- Cited by
- 28
- References
- 64
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 7 · 2023: 2
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Austrian MPS society (1R01HD102545-01A1)
- A Cure for Robert, Inc (1R01HD102545-01A1)
- The Carol Ann Foundation (1R01HD102545-01A1)
- Angelo R. Cali & Mary V. Cali Family Foundation, Inc. (1R01HD102545-01A1)
- The Vain and Harry Fish Foundation, Inc. (1R01HD102545-01A1)
- The Bennett Foundation (1R01HD102545-01A1)
- Jacob Randall Foundation (1R01HD102545-01A1)
- Nemours Funds (1R01HD102545-01A1)
- Institutional Development Award from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NICHD) (1R01HD102545-01A1)
- REGENXBIO Inc. (1R01HD102545-01A1)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis IVA, AAV8 gene therapy, sex differences, neutralizing antibodies, GALNS, N-acetylgalactosamine-6-sulfate sulfatase, lysosomal storage disease, articular cartilage, treatment efficacy
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Animals, Chondroitinsulfatases, Disease Models, Animal, Female, Humans, Male, Mucopolysaccharidoses, Mucopolysaccharidosis IV, Sex Characteristics, Genetic Therapy, Gene Expression, Capsid Proteins, Isovaleryl-CoA Dehydrogenase, Mice, Thyroxine-Binding Globulin, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.